Residual Paralysis Is More Common Than You Think

Slides:

Advertisements

Similar presentations

Matthias Eikermann, M.D., PhD

Advertisements

Dose-dependent Association between Intermediate-acting Neuromuscular-blocking Agents and Postoperative Respiratory Complications Source:Anesthesiology.

NAP5 The 5th National Audit Project ■ ■ ■ ■ ■ NAP5 The 5th National Audit Project ■ ■ ■ ■ ■ NAP5 The 5th National Audit Project ■ ■ ■ ■ ■ Neuromuscular.

Introduction. Adult ADHD in the Real World: From Clinical Trials to Clinical Practice.

Tharusan Thevathasan Eikermann Research Laboratory

Sensitivity Analyses Intraoperative neuromuscular blocking agent administration and hospital readmission Sub-cohort Frequency of readmitted patients (percent.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Moderate-to-Severe Asthma Management

Clinical Trials in IBD.

A Review of the Critical Role of Imaging in Primary Liver Malignancy

This program will include a discussion of off-label treatment not approved by the FDA for use in the United States.

Program Goals. The Importance of Neuromuscular Blockade Reversal for Enhancing Recovery of Surgical Patients.

T-Cell Exhaustion: Can We Overcome It in Cancer?

Advances in Managing Inhibitors in Patients With Hemophilia A

5 Things NPs and PAs Need to Know About Tardive Dyskinesia

Updates on Emerging GLP-1 Receptor Agonists

This program will include a discussion of off-label treatment and devices and investigational agents and devices not approved by the FDA for use in the.

Progression After Cancer Immunotherapy in Advanced NSCLC

Motor Fluctuations in Parkinson Disease: Options and Strategies

Modern Strategies for Basal Insulin Use in T2D

Misconceptions in Ambulatory Surgery

Reducing Postoperative Ileus

COPD Management.

Case Challenges in Chronic Migraine

Advances in Dry Eye.

Induction Chemotherapy for Patients With High-Risk or Secondary AML

Cost Effectiveness and Optimal Outcomes in HF

Treating Transplant-Ineligible Patients With Multiple Myeloma

Impact of the Introduction of Sugammadex

Improving Surgical Patient Safety

Differentiating Among the CDK 4/6 Inhibitors in the Management of Metastatic Breast Cancer.

Chronic Idiopathic Urticaria

Improving Surgical Outcomes

Addressing Disease Burden in Asthma

Asthma and Atopic Comorbidities

Optimizing Management of Advanced Bladder Cancer

Improving Management of Type 2 Diabetes in Hispanic/Latino Patients

Addressing Challenges in Factor VIII Inhibitors in Children With Hemophilia.

Management of CMV in HSCT Recipients

Evaluating Next-Generation BTK Inhibitors

بسم الله الرحمن الرحیم.

Hyperhidrosis Is Burdensome!

Gene Therapy: Past, Present, and Future

Immunotherapy for cSCC

Perspectives on the Impact of Inflammation in OA

EGFR-Mutated NSCLC and CNS Involvement: the Conundrum

New Recommendations on How to Stage Hidradenitis Suppurativa

When Is Biologic Therapy Appropriate for HS?

Parkinson Disease Psychosis

Updates in the Management of Acute Promyelocytic Leukemia

Scientific Update.

Guide to Atopic Dermatitis

Clinical Pearls on Hot Topics in MS

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Deep neuromuscular block to optimize surgical space conditions during laparoscopic surgery: a systematic review and meta-analysis M.H. Bruintjes, E.V.

Patient Questions and Expert Answers in Psoriasis:

Optimizing Joint Health in Hemophilia

This program will include a discussion of off-label treatment and investigational agents not approved by the Food and Drug Administration for use in the.

Novel Concepts in the Management of RCC

Improving Adherence to Antiplatelet Therapy After an ACS Event

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition

This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.

VKA Reversal and LVADs.

CDK4/6 Inhibitors.

The Nurse View: Spotlight on EGFR-Mutated NSCLC

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Immune Checkpoint Inhibitors in Lung Cancer

Foundations of Asthma.

Motor Fluctuations in PD

Presentation transcript:

Residual Paralysis Is More Common Than You Think

This program will include a discussion of off-label treatment not approved by the FDA for use in the United States.

Introduction

Use of Neuromuscular Blocking Agent Improves Intubation Conditions

Improved Tracheal Intubation Conditions Associated With Less Laryngeal Complications Postsurgery

Achieving Optimal Surgical Conditions

Deep NMB vs No NMB

Dose-Dependent Relationship Between NMBAs and Postoperative Respiratory Complications

NMBAs and Hospital Readmission

NMBAs and Residual Paralysis

Residual NMB

Risk Factors Associated With Postoperative Pulmonary Complications

Strategies to Prevent, Reduce, and Manage Residual Paralysis

Does Quantitative Monitoring Lead to Decreased Risk of AEs?

Quantitative Monitoring Reduces Incidence of Respiratory AEs

Proper Monitoring: Qualitative vs Quantitative

Neostigmine

Neostigmine (cont)

MGH Dept. of Anesthesia and Critical Care Pain Medicine Quality Improvement Project

MGH DACCPM Cognitive Aid

Results of MGH DACCPM Quality Improvement Project

Sugammadex

Sugammadex (cont)

How Much Sugammadex?

Contraindications for Sugammadex

Concluding Remarks

Abbreviations

Abbreviations (cont)